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Objectives The aim of the study was to evaluate the capability of 18F-FDG-PET/CT for 
the screening of musculoskeletal inflammation and injury of shoulder region. 
Materials and Methods The study included 122 participants (69 men, 53 women) who 
complained of shoulder pain at rest, and 122 age- and sex-matched controls who did not 
experience pain at rest. SUV values were calculated for both left and right shoulders and 
compared via a 4-point visual analog scale of subjective shoulder pain. Correlations 
between SUV values and uric acid (UA) and C-reactive proteins (CRP) were also 
evaluated. 
Results SUV values for shoulder joints with rest and/or motion pains were significantly 
higher than those of pain-free shoulder joints. SUV values associated with mild and 
severe pain at rest were significantly higher than those without resting pain, and SUV 
values associated with moderate and severe pain on motion were significantly higher 
than that those without motion pain. Furthermore, SUV values were significantly 
correlated with UA in men (β = 0.21, p = 0.02) and in all participants (β = 0.22, p < 
0.001). 
Conclusion 18F-FDG-PET/CT may be useful for the screening of musculoskeletal 
inflammation and injury of shoulder region. Since shoulder pain is common, especially 
among elderly individuals, we should carefully consider the necessity of further 
examination when identifying the uptake of 18F-FDG in shoulder joints. 
 






Shoulder pain is a common musculoskeletal problem that was reported in 7 % to 20 % 
of the adult population [1]. Shoulder pain is also one of the most common disorders 
affecting the musculoskeletal system and is becoming more common in today’s aging 
society [2]. It is also reasonable to think that the incidence of other shoulder conditions 
is increasing with the growth of the geriatric population. Generally, in the early stage, 
simple physical examination and radiographs are commonly used to analyze shoulder 
disorders. Nowadays, these simple examinations are complemented by ultrasound and 
magnetic resonance imaging (MRI), which both enable more detailed evaluation [2–8]. 
Recently developed fluorine-18-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) is an imaging modality that can detect the rate of glucose 
metabolization [9, 10], which is especially high in tumor [11–13] and inflammatory 
cells [14–16]. Furthermore, 18F-FDG PET/computed tomography (18F-FDG PET/CT) is 
a single imaging technique that provides both morphological and metabolic features of 
neoplastic lesions. This technique performs better than MRI for differentiating 
symptomatic lesions among the various lesions that present simultaneously within a 
particular region. This is because 18F-FDG PET reflects the difference in the uptake of 
FDG between the various tissues and bones based on their activity, and can therefore 
detect osteoblast activity or increased vascularity of clinically abnormal tissue. The 
technique also has the advantage of detecting any pathological lesion at a very early 
stage [17–20]. 
Furthermore, it has been suggested that incidental uptake of FDG may also represent 




Since shoulder pain frequently indicates musculoskeletal inflammation and injury, we 
recruited from a general population who participated in an 18F-FDG-PET/CT screening 
program; and evaluated the relationship between clinical symptoms, laboratory findings 
and the standardized uptake values (SUV: semi-quantitative parameter of ratio tracer 
uptake; regional FDG concentration normalized with the injected tracer dose and patient 
body weight) of shoulder joints. The aim of the study was to evaluate the capability of 







Materials and Methods 
 
Study participants and questionnaire 
We initially included 621 consecutive non-cancer subjects who underwent PET/CT 
screening for a cancer check-up at the Nishi-Isahaya Hospital PET/CT Diagnostic 
Imaging Center (Isahaya, Japan) between December 2010 and September 2011. The age 
of participants ranged from 25 to 87 (mean age: 59 years). Written informed consent 
was obtained from all 621 subjects. 
The demographic characteristics of each study participant (e.g., gender, age, medical 
history, etc.) were obtained by self-reported questionnaires. Participants also answered 
questions regarding pain (resting pain and motion pain) in right and left shoulders. 
Of the 621 study participants, 122 (69 men and 53 women) who complained of joint 
pain at rest were assigned to the “rest pain (+) group”, and 122 age- and sex-matched 
participants without resting pain were assigned to the “rest pain (−) group”. These 
participants assigned to the “rest pain (+) group” or “rest pain (−) group” were not asked 
whether they had motion pain. These 244 participants (488 shoulders) were included for 
further studies. 
Among these 244 participants, 85 individuals (51 men and 34 women) who 
complained pain on joint movement were assigned to the “motion pain (+) group”, and 
146 participants (79 men and 67 women) without motion pain were assigned to the 
“motion pain (−) group”. These participants assigned to the “motion pain (+) group” or 
“motion pain (−) group” were not asked whether they had resting pain. Among the 244 
participants, 131 participants (73 men and 58 women) with rest pain and/or motion pain 




(+) group” contained the participants with resting pain only, motion pain only, or both 
pain. In addition, 113 participants (65 men and 48 women) with neither resting nor 
motion pain were assigned to the “rest and/or motion pains (−) group”. 
Among 488 shoulders, 141 shoulders showed resting pain (rest pain (+) shoulder), 
whereas 347 shoulders did not (rest pain (−) shoulder); 54 shoulders showed motion 
pain (motion pain (+) shoulder), whereas 434 shoulders did not (motion pain (−) 
shoulder). Furthermore, 150 shoulders showed rest pain and/or motion pain (rest and/or 
motion pains (+) shoulder), whereas 338 shoulders showed neither rest nor motion pain 
(rest and/or motion pains (−) shoulder). 
Each participant who complained of shoulder pain was asked to indicate their 
perceived degree of pain via a 10-point visual analog scale (VAS) comprising 4 
categories, as follows: none (VAS 0); mild (VAS 1-3); moderate (VAS 4-6) and severe 
(VAS 7-10). 
Prior to the study, ethical approval was obtained from the ethics committee of 
Nagasaki University (project registration number 10121010). The study was conducted 
during a cancer screening program at the Nishi-Isahaya Hospital PET/CT Diagnostic 




The PET/CT imaging study was performed on a PET/CT scanner (Discovery ST; GE 
Healthcare [WI. USA]). Imaging was started 50 min after intravenous injection of 
18F-FDG through an anterior cubital vein. Injected FDG doses were determined 




182.1 to 400 MBq. The subjects fasted at least 6 hours before FDG injection and the 
glucose level of each subject was measured by a quick and easy method before FDG 
injection. When the glucose levels were > 200 mg/dl, the participants were excluded 
from this study. In 244 participants included in the study, the glucose level was 93 (71–
196) mg/dl [median (min–max)]. All patients were scanned in the turning up position 
with the arms down along the sides of the body. The image acquisition time was 2.5 min 
per bed position, with 7-8 bed positions, covering the whole body in a 
three-dimensional (3D) mode. The acquisition parameters for dual-detector helical CT 
were 140 kV, 30 mA, 3.75-mm slice thickness, and a pitch of 1.5. Attenuation correction 
was performed with acquired CT data. The PET/CT images displayed as coronal, 
sagittal, and transaxial slices were viewed on an Xeleris workstation (GE Healthcare). 
Details of this procedure are described elsewhere [21, 22]. 
 
Data collection and laboratory measurements 
Blood samples were collected from each subject after fasting overnight. High-sensitivity 
C-reaction protein (hs-CRP) and uric acid (UA) were measured using standard 
laboratory procedures. 
 
Evaluation of uptake 18F-FDG in shoulder joints 
The PET and CT images for each subject were analyzed using dedicated image analysis 
program on a personal computer. PET and CT images were superimposed as a fused 
PET/CT image using program, pMOD® (PMOD Technologies Ltd., Zürich, 
Switzerland). As the index of glucose metabolic activity in shoulder joints, SUVs in 




the 18F-FDG uptake. FDG uptake in bilateral shoulder joints was evaluated using a 
dedicated workstation to draw VOI covering each joint and calculate the SUVmax 
(maximum SUV value within each VOI) of each joint (Fig. 1). SUVmax was evaluated 
in right and left shoulder joints, respectively (Fig. 2). Mean-SUV was the average of 
SUVmax values in right and left shoulder joints; Max-SUV was the higher value of 
either right or left SUVmax. 
 
Statistical analysis 
Results are expressed as mean ± standard deviation or median (25th-75th quartiles). 
Differences in continuous values between men and women were compared using the 
t-test or Mann-Whitney U-test, and differences between categorized values such as 
frequency of joint pain were evaluated using the χ2 test. Correlations of SUV with age 
were evaluated by univariate linear regression analysis. SUV values of resting and 
motion pains were adjusted for age and compared by analysis of covariance (ANCOVA). 
The correlations of SUV values with UA and log hs-CRP adjusted for age were 
evaluated by multivariate linear regression analysis. As hs-CRP levels showed a skewed 
distribution, logarithmic transformation was performed for multivariate linear 
regression analysis. SUV values for each pain score were evaluated via the 
Kruskal-Wallis test. A p-value < 0.05 was considered to indicate statistical significance. 
All statistical analysis was performed using SPSS software (v. 18.0 for Windows; SPSS 







The characteristics of the study participants are shown in Table 1. 
The average age was not significantly different between men and women (58.8 ± 9.4 
years vs. 59.3 ± 11.5 years, p = 0.72). Frequencies of resting pain and motion pain were 
not significantly different between men and women (69 / 138 (50.0 %) vs. 53 / 106 
(50.0 %), p = 1.00; and 51 / 138 (39.2 %) vs. 34 / 106 (33.7 %), p = 0.38, respectively). 
Numbers of shoulder joints with both resting pain and motion pain were not 
significantly different between men and women (77 / 276 (27.9 %) vs. 64 / 212 (30.2 %), 
p = 0.58; and 27 / 276 (12.9 %) vs. 27 / 212 (15.0 %), p = 0.54, respectively). Also, 
numbers of shoulder joints with rest and/or motion pain were not significantly different 
between men and women (81 / 276 (29.3 %) vs. 69 / 212 (32.5 %), p = 0.45). 
Univariate linear regression analysis showed that SUV of right joints (R-SUV), SUV 
of left shoulder joints (L-SUV), Mean-SUV and Max-SUV of shoulder joints were 
positively correlated with age in men, women and all participants (Table 2). L-SUV and 
Mean-SUV were significantly higher in men than in women (1.36 (1.19-1.63) vs. 1.26 
(1.10-1.51), p = 0.02; and 1.39 (1.23-1.59) vs. 1.34 (1.17-1.47), p = 0.03, respectively), 
whereas R-SUV and Max-SUV were not significantly different between men and 
women (1.35 (1.20-1.59) vs. 1.28 (1.16-1.57), p = 0.14; and 1.51 (1.30-1.80) vs. 1.42 
(1.25-1.70), p = 0.056, respectively).  
SUV values of shoulder joints with rest and/or motion pain were significantly higher 
than those of shoulder joints without rest and/or motion pain. The difference remained 
significant even after adjustment for age. In addition, SUV values of shoulder joints 




and SUV values of shoulder joints with motion pain were significantly higher than those 
of shoulder joints without motion pain (Table 3). There was no significant difference in 
SUV value between the rest pain (+) and motion pain (+) groups (p = 0.156). 
When rest pain and motion pain were assessed according to perceived severity (none, 
mild, moderate and severe), SUV values were significantly higher in joints with mild 
and severe rest pain than those without rest pain. SUV values in joints with moderate 
and severe motion pain were significantly higher than those without motion pain (Table 
4 and Fig. 3). 
UA was significantly higher in men than in women (5.7 (5.1-6.6) g/l vs. 4.3 (3.7-5.0) 
g/l, p < 0.001). On the other hand, hs-CRP was not significantly different between men 
and women. Multivariate linear regression analysis adjusted for age revealed that 
Mean-SUV was significantly correlated with UA in men (β = 0.21, p = 0.02) and in all 
participants (β = 0.22, p < 0.001). On the other hand, Mean-SUV was not significantly 







In this study, we showed that R-SUV, L-SUV, Mean-SUV and Max-SUV of shoulder 
joints were positively correlated with age in men, women and all participants. Wandler 
et al. reported that, in patients undergoing 18F-FDG PET for clinical oncologic 
assessment, the maximum SUV over the entire shoulder joint showed a significant 
positive correlation with age, increasing by an average of 0.023 units for each 1-year 
increase in subject age [18]. Takiguchi et al. found a significant positive correlation 
between the mean SUVmax of trapezius muscle and subject age in individuals with 
chronic neck/shoulder pain [23]. Our current results are consistent with such previous 
studies. 
Our study also demonstrated that SUV values of shoulders with rest and/or motion 
pain were significantly higher than those of shoulders without rest and/or motion pain. 
Previously, Kubota et al. demonstrated that, in patients with rheumatoid arthritis (RA), 
SUVmax for large painful/swollen joints throughout the whole body were significantly 
higher than those of non-painful/swollen joints [17]. As far as we know, our study is the 
first to show the uptake of 18F-FDG in shoulder joints in subjects with shoulder pain 
without rheumatic disorders. This uptake probably reflects local inflammation and its 
metabolic activity. When identifying uptake of 18F-FDG in subjects with non-rheumatic 
disorders, we should carefully consider the necessity of further examination, including 
the collection of clinical symptoms and signs, X-ray, ultrasound and magnetic resonance 
imaging (MRI). 
Using VAS values, we showed that, to some extent, SUV values reflect patients’ 




evaluated by the uptake of 18F-FDG in shoulder regions. Recently, Masala et al. reported 
that, in bone lesion with metastases of bone tumor, changes in SUVmax and VAS values 
were not significantly correlated [24]; however, all subjects in that study were cancer 
patients and the number of participants (n = 20) was much smaller than in the present 
study. Further studies are needed to clarify the relationship between the perceived 
degree of shoulder pain and SUV values. 
Interestingly, we found that FDG uptake in shoulder joints was significantly 
correlated with UA level in males and in all participants, even after adjustment for age. 
It is well known that gout due to hyperuricemia frequently affects the feet, hands, wrists, 
elbows and knees, whereas gout of the shoulder is rare [25, 26]. However, our current 
results suggest that — especially in males — relatively high UA level may be a risk 
factor for inflammation of the shoulder joint and, subsequently, shoulder pain. Since it is 
possible to collect information on SUV in other joints, including metatarsophageal 
joints that are frequently affected by gout, further investigations are warranted to clarify 
the involvement of uric acid in the development of shoulder pain. 
On the other hand, we could not clarify the association between FDG uptake in 
shoulder joints and CRP. In patients with rheumatoid arthritis (RA), it has been reported 
that FDG uptake in inflamed RA joints may reflect disease activity [27]. Beckers et al. 
used 18F-FDG PET to assess synovitis in patients with RA and showed that cumulative 
SUV and the number of PET-positive joints were significantly correlated with CRP [28]. 
They also showed that change in SUV due to initiation of anti-TNF-α treatment was 
correlated with changes in serum CRP, as well as MRI parameters and 
metalloproteinase-3 (MMP-3) levels [29]. Since our subjects were not patients with RA 




than in patients with RA. Such differences in baseline CRP levels may account for the 
difference in the results compared with other studies involving RA patients. 
Several limitations of this study warrant mention. Since we enrolled subjects who 
participated in cancer screening by PET/CT, selection bias might occur at this stage. We 
could not obtain final diagnosis of shoulder pain by further examination, such as 
shoulder X-ray and MRI. Also, since we used VAS values to evaluate severity of 
shoulder pain, the data are subject to differing perceptions between individuals. 
Furthermore, we could not evaluate inflammation markers (such as MMP-3, TNF-α) 
other than CRP. Further studies are needed to clarify the mechanism of 18F-FDG uptake 







The findings suggest that FDG-PET/CT might be useful in screening musculoskeletal 
inflammation and injury of the shoulder region. Since shoulder pain is common, 
especially among elderly individuals, we should carefully consider the necessity for 
further examination when identifying the uptake of 18F-FDG in shoulder joints, even in 
subjects with non-rheumatic disorders. 
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 Table 1 Characteristics of study participants 
Variables Men Women All p 
Age (y) 58.8 ± 9.4 59.3 ± 11.5 59.0 ± 10.4 0.72 
Number with resting pain, n (%) 69 (50) 53 (50) 122 (50) 1.00 
Number of shoulder joints with rest pain, n (%) 77 (27.9) 64 (30.2) 141 (28.9) 0.58 
Number with motion pain, n (%) 51 (39.2) 34 (33.7) 85 (36.8) 0.38 
Number of shoulder joints with motion pain, n (%) 27 (12.9) 27 (15.0) 54 (13.8) 0.54 
Number with rest and/or motion pains, n (%) 73 (52.9) 58 (54.7) 131 (53.7) 0.78 
Number of shoulder joints with rest and/or motion pains, n (%) 81 (29.3) 69 (32.5) 150 (30.7) 0.45 
R-SUV (max) 1.35 (1.20-1.59) 1.28 (1.16-1.57) 1.33(1.18-1.58) 0.14 
L-SUV (max) 1.36 (1.19-1.63) 1.26 (1.10-1.51) 1.31 (1.16-1.54) 0.02 
Mean-SUV 1.39 (1.23-1.59) 1.34 (1.17-1.47) 1.37 (1.21-1.56) 0.03 
Max-SUV 1.51 (1.30-1.80) 1.42 (1.25-1.70) 1.48 (1.27-1.75) 0.056 




hs-CRP (g/l) 0.045 (0.019-0.110) 0.033 (0.017-0.065) 0.039 (0.018-0.087) 0.054 
Values are mean ± standard deviation, number (percentage), or median (25th-75th percentile). 
SUV, standardized uptake value; R-SUV, right-standardized uptake value; L-SUV, left-standardized uptake value; UA, uric acid; hs-CRP, 





Table 2 Correlation coefficients for univariate regression analysis of SUV with age 
Variables Men Women All participants 
R-SUV (max) 0.16 0.43** 0.29** 
L-SUV (max) 0.24** 0.44** 0.33** 
Mean-SUV 0.22* 0.48** 0.34** 
Max-SUV 0.15 0.43** 0.28** 
*p < 0.05 and **p < 0.01. 

















*median (25th-75th percentiles) 
SUV, standardized uptake value.
Types of pain SUV values* p p, Age-adjusted 
   Men Women All participants 
Rest and/or motion pains      
(+) 1.42 (1.23-1.74) 
< 0.001 0.02 < 0.001 < 0.001 
(−) 1.29 (1.16-1.51) 
Rest pain      
(+) 1.41 (1.23-1.73) 
< 0.001 0.02 < 0.001 < 0.001 
(−) 1.29 (1.16-1.51) 
Motion pain      
(+) 1.51 (1.26-1.91) 
< 0.001 0.1 < 0.001 < 0.001 




Table 4 Perceived degree of rest and motion pains and SUV values 
 None Mild Moderate Severe p 
Rest pain scale 1.29 (0.89-3.29) 1.43 (0.93-2.67) ** 1.35 (0.90-2.83) 1.58 (1.04-2.36) * 0.005 
Motion pain scale 1.29 (0.89-3.29) 1.41 (1.02-2.06) 1.54 (1.02-2.83) *** 1.80 (1.13-2.36) * < 0.001 
Values are median (min-max). 





Table 5 Multivariate regression analysis of Mean-SUV adjusted by age and sex  
β, Standardized regression coefficient; CI, Confidence interval; UA, uric acid; 
hs-CRP, high-sensitivity C-reaction protein. 
Variables  β 95% CI p 
UA     
 All 0.22 0.022, 0.076 < 0.001 
 Men 0.21 0.009, 0.092 0.02 
 Women 0.14 − 0.010, 0.088 0.12 
log hs-CRP     
 All 0.09 − 0.018, 0.107 0.16 
 Men 0.07 − 0.049, 0.122 0.41 






Fig. 1 The volume of interest (VOI) covering each joint at the coronal, sagittal, and 
transaxial slices of fused PET/CT images and the SUVmax (maximum SUV value 
within each VOI) of each joint were automatically calculated. 
 
Fig. 2 Typical finding of cases that showed total (a) (SUV = 2.36) and partial (b) 
uptakes of 18F-FDG in shoulder joints (SUV = 3.27). Shoulder joint without uptake 
of 18F-FDG (SUV = 0.89) (c). 
 
Fig. 3 Perceived severity of pain and uptake of 18F-FDG. Severe shoulder joint pain 
at rest and motion, and SUV was 2.36 (a). Mild shoulder rest and motion joint pain, 
and SUV was 0.93 (b). 



